Andrew Hiatt

Dr. Andrew Hiatt, Vice President, Research & Development, Epicyte Pharmaceuticals, received his Ph.D. in Biochemistry from Columbia University, trained at the Cold Spring Harbor Laboratories and served as a faculty member in the Departments of Cell Biology and Molecular Biology at The Scripps Research Institute. Dr. Hiatt is a co-inventor of technology for the production of antibodies in plants and Epicyte's proprietary transport technology. Hiatt brings to Epicyte extensive experience in biochemistry, nucleic acid chemistry, expression of transgenic proteins, and antibody engineering. Dr. Hiatt is a Founder of Epicyte and a member of the Board of Directors. Epicyte Pharmaceuticals is a corporate nominee for the 2002 World Technology Award for Biotechnology. Epicyte's founding scientists, Drs. Andrew Hiatt and Mich Hein, collaborated for several years as faculty members of The Scripps Research Institute in La Jolla, California. Hiatt and Hein went on to invent Plantibodies^(TM) technology which explores green plants as producers of various immunoactive proteins. Funding for the June 1996 Epicyte Pharmaceutical, Inc., launch was arranged with equity capital from private investors; Epicyte then were awarded several federal research grants and attracted additional venture funding from CMEA, Viridian Capital, TD Javelin, and the Dow Chemical Company. Three years later, with its first yield of Plantibodies^(TM) crop in 1999, Epicyte achieved a scientific breakthrough and commercial milestone. Since that time, its corporate headquarters in the biotech "boomtown" of San Diego's high-tech Sorrento Valley has grown to include more than 40 employees. To date, Epicyte has forged nearly 10 alliances, including partnerships with public companies such asMedarex, Inc.,ÊDow Chemical and Dow AgroSciences, the British companyÊBiovation, and the Johnson & Johnson subsidiary,ÊCentocor. Ongoing collaboration with theÊNational Institutes of HealthÊhas awarded Epicyte with its fifth NIH grant that supports the Company's antibody-based research toward solutions for sexually transmitted disease.


Follow us

Twitter icon
Facebook icon
Google+ icon
LinkedIn icon
instagram icon

Copyright @ The World Technology Network. All Rights Reserved Back to Top

Back to Top